Tolcapone: a review of its use in the management of Parkinson's disease.

Article Details

Citation

Copy to clipboard

Keating GM, Lyseng-Williamson KA

Tolcapone: a review of its use in the management of Parkinson's disease.

CNS Drugs. 2005;19(2):165-84.

PubMed ID

15697329 [ View in PubMed

]

Abstract

Tolcapone (Tasmar) is a selective, reversible inhibitor of peripheral and central catechol-O-methyltransferase (COMT). Results of well designed studies indicate that oral tolcapone is an effective adjunct to levodopa plus a peripheral dopa-decarboxylase inhibitor (DDCI) in patients with fluctuating Parkinson's disease. Tolcapone significantly improves levodopa-induced motor fluctuations and significantly reduces levodopa requirements. The drug is generally well tolerated, with the most commonly occurring adverse events being dopaminergic related. Thus, tolcapone is a useful option in patients with fluctuating Parkinson's disease who are receiving levodopa/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.

DrugBank Data that Cites this Article

Drugs

Tolcapone

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Tolcapone	Catechol O-methyltransferase	Protein	Humans	Yes	Inhibitor	Details